23andMe Holding Co. (NASDAQ:ME) Q2 2023 Earnings Conference Call November 7, 2022 4:30 PM ET

Company Participants

Wade Walke - Vice President-Investor Relations

Anne Wojcicki - Chief Executive Officer & Co-Founder

Joe Selsavage - Interim Chief Financial Officer & Accounting Officer

Kenneth Hillan - Chief Therapeutics Officer

Conference Call Participants

Tiago Fauth - Credit Suisse

Steven Mah - Cowen

Operator

Good day, and thank you for standing by. Welcome to the 23andMe's Fiscal Year 2023 Second Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your host today, Wade Walke, Vice President, Investor Relations. Please go ahead.

Wade Walke

Thank you. Before we begin, I encourage everyone to go to investors.23me.com to find the press release we issued earlier today reporting our financial results for the quarter. A replay of today's webcast will also be available on our website for a limited time within 24 hours after the event.

Please note that certain statements made during this call regarding matters that are not historical facts, including but not limited to management's outlook or predictions for future periods are forward-looking statements. These statements are based solely on information that is now available to us. We encourage you to review the section entitled Forward-Looking Statements in our press release, which applies to this call. Also please refer to our SEC filings, which can be found on our website and the SEC's website for a discussion of numerous factors that may impact our future performance. We also discuss certain non-GAAP measures. Important information on our use of these measures and reconciliation to US GAAP may be found in our earnings release.

Joining us on our call today are Anne Wojcicki, our Chief Executive Officer and Co-Founder; and Joe Selsavage, our Interim Chief Financial Officer and Accounting Officer. Kenneth Hillan, our Chief Therapeutics Officer will join us for Q&A.

And now I'd like to turn the call over to Anne.

Anne Wojcicki

Thank you, Wade. In this last quarter, we continue to make progress on building a foundation to deliver personalized healthcare to consumers. Our genetic database is now at 13.4 million genotype customers. It is the world's largest recontactable database for genetic research, which makes us best positioned to unlock the potential of the human genome to treat and prevent disease.